What does Marker Therapeutics, Inc. do?
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the…
What is Marker Therapeutics, Inc.'s P/E and P/B ratio?
Marker Therapeutics, Inc. has a P/E ratio of -2.5 and a P/B ratio of 1.47.
What is Marker Therapeutics, Inc.'s debt-to-equity ratio?
Marker Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Marker Therapeutics, Inc. owe compared with what it owns?
Marker Therapeutics, Inc. owes $0.17 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Marker Therapeutics, Inc.'s Positivity rank?
Marker Therapeutics, Inc. is ranked #2,628 of 6,774 companies globally and #895 of 4,000 in United States on PositoAI, with a Positivity Score of 21,309.
Does Marker Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Marker Therapeutics, Inc..
Where can I read the latest news about Marker Therapeutics, Inc.?
Recent headlines about Marker Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Marker Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Marker Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.